Evaluation of Seropositivity after Standard Doses of Vaccination against SARS-CoV-2 in Early Breast Cancer Patients Receiving Adjuvant Treatment

Jinyong Kim^{1*} & Euijin Chang^{1*}, Song Yi Park¹, Dae-Won Lee¹, Chang Kyung Kang¹, Pyoeng Gyun Choe¹, Nam Joong Kim¹, Myoung-don Oh¹, Wan Beom Park¹ & Kyung-Hun Lee^{1,2}, Seock-Ah Im^{1,2}

Author affiliations

¹ Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea

² Cancer Research Institute, Seoul National University, Seoul, Korea

*Co-first authors

Correspondence to

Kyung-Hun Lee, MD, PhD

Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongro-gu, Seoul 03080, Republic of Korea

Tel: 82-2-2072-7207, E-mail kyunghunlee@snu.ac.kr

Wan Beom Park, MD, PhD

Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongro-gu, Seoul 03080, Republic of Korea

Tel: 82-2-2072-3596, E-mail wbpark1@snu.ac.kr

Author Contributions

K.L. and W.P. conceptualized the study and set methodology. J.K. and E.C. performed data collection, formal analysis and interpretation. All authors performed data curation. K.L. and W.P. supervised the study. J.K. and E.C. wrote original manuscript. All authors reviewed and provide final approval of the manuscript.

Keywords: COVID-19, SARS-CoV-2 vaccines, breast cancer, adjuvant chemotherapy, antispike antibody

1 Abstract

2 Background

3 Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals and 4 patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have 5 been developed and used for patients with cancer, but scarce data is available on their 6 efficacy in patients under active anti-cancer therapies.

7 Materials and Methods

8 In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the 9 anti-spike protein subunit 1 of SARS-CoV-2 after vaccination in early breast cancer patients 10 with concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no 11 treatments.

12 Results

Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with early breast cancer, regardless of the type of anticancer therapies. However, the postvaccination serum anti-spike antibody titers were significantly lower in the patients under cytotoxic chemotherapy.

17 Conclusion

Our study emphasizes the importance of the personalized risk stratification and considerationfor booster doses in more vulnerable populations.

20

21 Implications for Practice

22 In this article, we present rare data on the homogeneous population of patients with early

23 breast cancer under active anti-cancer treatments. The patients showed adequate serologic 24 responses against SARS-CoV-2 virus after standard doses of vaccination without serious 25 adverse events in concurrence with active adjuvant anti-cancer therapy. The patients 26 receiving concurrent cytotoxic chemotherapy, however, have significantly lower serum anti-27 spike antibody titers than those under non-cytotoxic anti-cancer treatments or without 28 treatments. Selection of the COVID-19 vaccines should be based on personalized risk 29 stratification considering the use of concurrent cytotoxic chemotherapy and the patient's 30 medical circumstances. Booster doses of vaccination could be considered for the vulnerable 31 population, such as elderly with comorbidities and the single standard dose of vaccination.

32

34 Introduction

Coronavirus disease 2019 (COVID-19) pandemic had affected over the world with 308 million confirmed cases and 5.49 million deaths as of January 12, 2022¹. Standard doses of authorized vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which included BNT162b2 vaccine (Pfizer–BioNTech (PZ)), mRNA-1273 vaccine (Moderna), Ad26.COV2.S vaccine (Janssen)², and AZD1222 vaccine (Oxford-AstraZeneca (AZ)), provided comparable efficacy in preventing symptomatic COVID-19 with the acceptable safety profile³⁻⁶.

Patients with cancer have an increased mortality rate due to COVID-19, and are considered as a prioritized group in need of vaccination by most authorized global guidelines ⁷⁻¹². Nonetheless, patients with cancer under systemic treatments were largely excluded from the previous clinical trials conducted to assess the efficacy of the COVID-19 vaccines. Although recent studies reported that the standard dose of vaccine induced adequate responses in patients with cancers, data on each specific solid cancer needs further investigation ^{13,14}.

Breast cancer is the leading cause of the cancer deaths in female ¹⁵. Especially, the early breast cancer confined to the breast and regional lymph nodes accounts for majority of the total cases ^{16,17}. Treatments of early breast cancer are usually composed of various modalities including surgery, radiotherapy, hormonal therapy, molecular targeted therapy, and chemotherapy with corticosteroid prophylaxis ¹⁶. Thus, the effect of COVID-19 vaccination should be reevaluated among the patients with early breast cancer who are currently under different anti-cancer treatments.

56 This study is a prospective study evaluating the serologic responses from standard doses 57 of COVID-19 vaccines in the patients with early breast cancer, by comparing the antibody

58	responses in the patients on cytotoxic chemotherapy with those in the patients on the other
59	anti-cancer treatments. We also investigated whether the adjunct corticosteroid affected the
60	immunologic responses to vaccines in the patients with early breast cancer.

61

62 Materials and methods

63 Study design and subjects

64 This is a prospective, longitudinal cohort study that commenced recruitment in April 2021 65 at Seoul National University Hospital. Early breast cancer patients who are 20 years or older 66 with the past or current history of systemic anti-cancer treatments for breast cancer, including 67 cytotoxic chemotherapy, molecule-targeted therapy, and endocrinal therapy were enrolled. 68 Early breast cancer was defined as the disease confined to the breast with or without regional 69 lymph node involvement, and without distant metastatic disease. The patients who were 70 currently under chemotherapy within 28 days of vaccination were included in the cytotoxic 71 chemotherapy group; patients under targeted therapy and endocrinal therapy were in non-72 cytotoxic anti-cancer treatment group; patients who did not receive any anti-cancer treatment 73 within 28 days of vaccination were in control group. The patients received standard doses of 74 vaccines, which were either two doses of PZ, Moderna, AZ, or a single dose of Janssen. The 75 patients who had active infectious diseases or received immune-suppressants or organ 76 transplant were excluded.

77 The chemotherapy regimen included anthracyclines, cyclophosphamide, docetaxel, 78 paclitaxel, carboplatin, and capecitabine. Molecular target agents included trastuzumab and 79 pertuzumab. Hormonal therapies were chosen among tamoxifen, letrozole, and anastrozole 80 depending on the patient's menopausal status and clinical conditions. The association

between corticosteroid use and vaccination was also assessed in the patients who used
corticosteroid over 10mg of prednisolone or equivalent dose within 14 days of vaccination ¹⁴.

83 Our primary endpoint was the immunogenicity of the COVID-19 vaccine in the patients 84 with early breast cancer under active systemic anti-cancer treatment, defined by the 85 proportion of patients who achieved positive anti-spike (anti-S1) antibody titer after 86 vaccination. Secondary outcomes included the association of the prior use of corticosteroids 87 to immunogenicity of vaccines. Clinical data and samples were collected before the 88 vaccination, between 21 to 28 days after the first and the second dose of vaccination, 89 respectively. The study was approved by the Institutional Review Board (IRB No. 2103-121-90 1206). Written informed consent was obtained from all participants prior to vaccination. All 91 the data from the patients were anonymized and de-identified prior to analysis.

92

93 S1-reactive IgG ELISA

94 We evaluated the antibody responses at baseline and at 3 weeks after each vaccination. We 95 semi-quantitatively measured the concentration of the immunoglobulin G against the anti-S1 96 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Enzyme-linked 97 immunosorbent assay (anti-S1 IgG ELISA) (Euroimmun, Lübeck, Germany) according to the 98 manufacturer's instructions. The immunoassay was granted Emergency Use Authorization by 99 the US Food and Drug Administration. The cut-off index (COI) of optical density ratio (OD 100 ratio) greater than or equal to 1.1 was considered seropositive; COI lower than 0.8 was 101 considered negative; and the rest was considered borderline according to the manufacturer's 102 instructions. Borderline results were considered as negative for analysis.

104 Statistical analyses

105 Categorical variables were summarized with the frequencies in number and rates in 106 percentages. Continuous variables were represented with the median values and ranges. 107 Differences were assessed using Mann-Whitney test for continuous variables and Pearson's 108 χ^2 or Fisher's exact test for categorical variables. P-values of <0.05 were considered 109 statistically significant. The association between treatment with cytotoxic chemotherapy and 110 the anti-S1 IgG OD ratio in post-vaccination serum was evaluated using a multivariate linear 111 regression model. The anti-S1 IgG OD ratio was set as the dependent variable and the 112 treatment with cytotoxic chemotherapy was set as the independent variable. Additional 113 covariates were age and type of vaccines. The association between treatment with cytotoxic 114 chemotherapy and the seropositivity based on OD ratio was evaluated using a logistic 115 regression model. Data and statistical analyses were performed in R version 4.1.2 and 116 RStudio version 2021.09.1.

117

118 **Results**

119 Patient characteristics

We recruited 112 patients with early breast cancer who received adjuvant cytotoxic chemotherapy and at least one dose of COVID-19 vaccine. Twelve patients withdrew from the study, and another twelve samples were not available for the analysis at the time of data collection. One case was excluded because of the high baseline anti-S1 antibody level, suggestive of COVID-19 infection prior to vaccination (Figure 1). Of all, 80.5% (70 of 87) received PZ; 10.3% (9 of 87) received Moderna; 3.4% (3 of 87) received Janssen; 5.7% (5 of 87) received AZ. Except for the three patients who received single dose of Janssen, 84

127 patients received two doses of vaccines without cross-injection. The median interval between 128 the first and second vaccination was 42 days (range, 21-77). The median age of patients was 129 52 years (range 35-69) and all were female. Within 28 days of vaccination, 36.8% (32 of 87) 130 underwent cytotoxic chemotherapy and 9.2% (8 of 87) had combination with targeted therapy. 131 Patients who received non-cytotoxic anti-cancer therapy were 42.5% (37 of 87). Only one 132 patient was under molecular targeted therapy, and other 36 patients were under endocrinal 133 therapy. The patients who had no anti-cancer treatment within 28 days of vaccination were 134 20.7% (18 of 87). No serious adverse events were reported. The patient characteristics are 135 shown in Table1.

136

137 Vaccine immunogenicity with active chemotherapy

Overall, 96.6% (84 of 87) were seropositive after completion of vaccinations. After first dose, 70.1% (61 of 87) were seropositive, and additional 25.3% (22 of 87) gained seropositivity after second dose (Figure 2, Table S1). Three patients failed seroconversion; two were in borderline range and one was seronegative. Two patients in borderline range received two doses of PZ vaccine during adjuvant doxorubicin and cyclophosphamide chemotherapy. The only seronegative patient received one dose of Janssen while on letrozole (Table S2).

Only 31.2% (10 of 32) in the chemotherapy group, compared with 91.9% (34 of 37) in the non-cytotoxic treatment group and 94.4% (17 of 18) in the control group, achieved the adequate immunoglobulin level after the first dose. However, the majority (93.8%, 30 of 32) of the patients in chemotherapy group achieved seropositivity after the second dose. In the non-cytotoxic treatment group and control group, all patients who received two doses of vaccination were seropositive. There was no significant difference in seroconversion rate

after the completion of vaccination among the cytotoxic chemotherapy group, non-cytotoxic
treatment group, and control group (93.8% vs. 97.3% vs. 100%, p=0.234). No significant
association was observed in seropositivity regarding age, types of vaccines, and treatments
with cytotoxic chemotherapy (Table S3).

Anti-S1 antibody levels increased gradually with each vaccination in all patients, with more than 50 folds after the first dose and 137 folds after the second dose (Figure S1). Both mRNA or adenovirus vector vaccines showed significant increase in antibody titers (Figure S2), and no significant difference was observed in the anti-S1 antibody titer at each time point.

159 When the antibody titers in the chemotherapy group, the non-cytotoxic treatment group, 160 and the control group were compared, the antibody titers also significantly and gradually 161 increased in all groups after the first and second vaccinations. Despite similar baseline levels, 162 however, significantly lower magnitudes of antibody titers was observed in patients who had 163 concurrent cytotoxic chemotherapy, compared to those in the non-cytotoxic treatment group 164 or those in the control group after first vaccination (cytotoxic chemotherapy vs. non-cytotoxic 165 treatment vs. control, 10.7 vs. 84.2 vs. 69.8-fold increase respectively, p<0.001) and second 166 vaccination (95.4 vs. 142.1 vs. 132.4-fold increase respectively, p<0.001 for cytotoxic vs. 167 non-cytotoxic and p=0.005 for cytotoxic vs. control) (Figure 3, Table 2). In the linear 168 regression and multiple regression analyses adjusted for age, the treatment with cytotoxic 169 chemotherapy remained as a significant factor for predicting low anti-S1 antibody titer 170 (p<0.001). No significant association was observed between the antibody titers with types of 171 vaccines (Table S4, S5).

172

173 *Vaccine immunogenicity with corticosteroid use*

Corticosteroid was used within 14 days before the vaccination in 20.9% (18 of 87) of the patients, all of whom were in the chemotherapy group. The association between corticosteroid use and antibody titer was only assessed in chemotherapy group to control the effect of chemotherapy to immunogenicity. There was no significant difference in the antibody titers between the patients who received corticosteroid in concurrence with chemotherapy and those who only received chemotherapy at the time of vaccination (Figure 4).

181

182 **Discussion**

183 In this prospective study, standard regimen of COVID-19 vaccination generated sufficient 184 amount of IgG antibody titers against SARS-CoV-2 virus in most of the early breast cancer 185 patients who had adjuvant anti-cancer treatments. The rate of seropositivity was numerically 186 comparable to that of the previous studies performed in patients with cancer 13,14,18,19 . It is 187 well known that the anti-spike antibody titer is correlated with the protection from COVID-19²⁰⁻²³. The emergence of neutralizing antibodies at early onset was associated with the 188 189 shorter time for negative conversion of swab culture, while the lack of neutralizing antibody was associated with a fatal outcome in symptomatic COVID-19 patients²⁰. Known as a good 190 surrogate marker of neutralizing antibody titers ^{20,23}, the anti-spike antibody levels measured 191 192 with EUROIMMUN ELISA kit also reported strong positive correlation with the neutralizing antibody titers assessed by a microneutralization assay ²¹. All in all, patients with breast 193 194 cancer under concurrent adjuvant cytotoxic chemotherapy, when compared with those under 195 molecular targeted therapy, endocrine therapy, or no anti-cancer treatments, were capable of 196 acquiring adequate protections against COVID-19 infection after vaccinations, irrespective of 197 age and types of vaccines.

198 Cytotoxic chemotherapy, however, was significantly associated with lower IgG antibody 199 titers after both first and second dose of vaccinations despite the equivalent seroconversion 200 rate. About 7.8-fold difference was observed between the cytotoxic chemotherapy group and 201 non-cytotoxic treatment group after the first dose of vaccine, which decreased to 1.5-folds 202 after the second dose. A cohort study reported that the anti-spike IgG titers of patients with 203 solid cancer was 3.7-folds lower than those of healthy relatives after the second dose of Pfizer vaccination ¹³. Moreover, two of the patients were under adjuvant cytotoxic chemotherapy 204 205 before PZ vaccine showed borderline range of anti-S1 IgG levels. In PZ vaccination trial, the 206 median IgG titer was statistically significantly lower in the patients under active cancer treatments with healthy controls ¹³. Booster dose of vaccinations may be considered in the 207 208 cancer patients under active cytotoxic treatments for a robust protection against SARS-CoV-2.

209 The only patient who was seronegative had received one dose of Janssen while on 210 endocrinal therapy, and had completed cytotoxic chemotherapy 47 days before vaccination. 211 Meanwhile, two other patients who had received Janssen vaccine experienced sufficient 212 seroconversion after the first dose between cycles of cytotoxic chemotherapies. One possible 213 speculation would be their ages. The seronegative patient was over 65 years old while other 214 two seropositive patients were in their 40s and 50s. In the phase I/II trial of Janssen vaccine, the participants of 60 years or older had lower incidence of seroconversion 24 . In the subgroup 215 216 analysis of ENSEMBLE trial, lower efficacy of preventing the severe-critical COVID-19 was observed among participants of 60 years or older with comorbidities ⁶. Individual medical 217 218 circumstances should be taken into account in choosing the type of vaccines, and booster 219 doses should be considered for vulnerable populations.

The non-cytotoxic treatment group treated with endocrinal therapy and monoclonal anti-HER-2 therapy showed similar seroconversion rates and anti-S1 antibody titers when

medRxiv preprint doi: https://doi.org/10.1101/2022.07.23.22277888; this version posted July 24, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

compared to control group. Previous study reported higher rates of post-vaccination seroconversion in patients on endocrine therapy including ovarian function suppression and aromatase inhibitors compared with the other groups ¹⁸. Only scarce data was available regarding the impact of the trastuzumab to the efficacy of the vaccines. One study about influenza vaccination reported that breast cancer patients receiving adjuvant trastuzumab had sufficient increase of immunogenicity and equivalent serological protection rate as healthy controls ²⁵.

229 It had been widely believed that the use of systemic corticosteroid may affect T and B cell 230 functions. For example, patients with sustained high-dose corticosteroids were associated with poor pneumococcal polysaccharide vaccine response and more infections²⁶. In our study, 231 232 corticosteroids over 10mg of prednisolone or equivalent dose within 14 days of vaccination 233 apparently seemed to diminish the amount of antibody titers. But corticosteroids were 234 administered as the premedication for taxanes, and none of the control group used 235 corticosteroids. When the factor of cytotoxic chemotherapy was adjusted, there was no 236 difference in the antibody titers with corticosteroid treatments. A recent study also reported 237 that the short term use of corticosteroids significantly relieved side effects without hindering immunogenicity after the first dose of AZ vaccine²⁷. In our study, adjunctive corticosteroids 238 239 were used shortly, and thus minimally impeded the immunologic responses driven by 240 vaccines.

Our data is limited by the relatively small number of patients, especially those who had adenovirus vector vaccines. Unfortunately, only one patient was treated with trastuzumab that the analysis of the effect of molecular target therapy on immunogenicity of vaccines was unavailable. Immune checkpoints inhibitors, which are not yet approved as adjuvant treatment for breast cancer, were not included in the study. However, this study was

246	successful in recruiting a homogeneous population of the early breast cancer patients
247	undergoing adjuvant anti-cancer treatments. We also evaluated the effects of corticosteroid
248	use to the seroconversion, which is commonly used in adjunct to cytotoxic chemotherapy.
249	Another pitfall was the possibility of the seroconversion by asymptomatic COVID-19
250	infections, because the regular COVID-19 PCR screenings were not done. T cell responses,
251	known as important in immunity against COVID-19, were also not evaluated. Further studies
252	with more patient data would strengthen our knowledge in understanding the immunologic
253	responses after vaccination in the patients with cancer.

254

255

256 Conclusion

Patients with early breast cancer undergoing adjuvant anti-cancer therapy showed adequate serologic responses against SARS-CoV-2 virus after vaccination without serious adverse events. Selection of the COVID-19 vaccines should be personalized, taking the patient's medical circumstances into account. Booster doses of vaccination could be considered for the vulnerable populations.

- 263 Reference:
- 264 1. Coronavirus Disease (COVID-19). (January 12, 2022)
- 265 2. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19
- 266 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat
- 267 *Rev Immunol.* Oct 2021;21(10):626-636. doi:10.1038/s41577-021-00592-1
- 268 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA

- 269 Covid-19 Vaccine. *New England Journal of Medicine*. 2020;383(27):2603-2615.
 270 doi:10.1056/NEJMoa2034577
- 4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19
- vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled
- 273 trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
- doi:10.1016/S0140-6736(20)32661-1
- 5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
- 276 CoV-2 Vaccine. New England Journal of Medicine. 2020;384(5):403-416.
- 277 doi:10.1056/NEJMoa2035389
- 278 6. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
- 279 Vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187-2201.
- 280 doi:10.1056/NEJMoa2101544
- 281 7. NCCN. Cancer and COVID-19 Vaccination version 4.0. Accessed January 12, 2022,
- 282 https://www.nccn.org/docs/default-source/covid-19/2021_covid-
- 283 19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70
- 284 8. Marina Chiara Garassino NG, Petros Grivas, Karin Jordan, Francesca Lucibello, Olivier
- 285 Mir, George Pentheroudakis, Florian Scotté, Marie von Lilienfeld-Toal, Giuseppe Curigliano,
- 286 John Haanen, Uwe Gerd Liebert, Florian Lordick, Ignacio Melero, Corinna Pietsch, and
- 287 Solange Peters. COVID-19 vaccination in cancer patients: ESMO statements. . Accessed
- January 12, 2022, https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
- 289 9. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in
- 290 patients with cancer. *Nature Medicine*. 2020/08/01 2020;26(8):1218-1223.
- 291 doi:10.1038/s41591-020-0979-0
- 292 10. Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region:
- adverse outcomes in patients with cancer. Nature Cancer. 2020/08/01 2020;1(8):784-788.

294 doi:10.1038/s43018-020-0104-9

- 295 11. Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 Treatments and 296 Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium 297 (CCC19) Cohort Study. Cancer Discov. 2020;10(10):1514-1527. doi:10.1158/2159-8290.CD-298 20-0941 299 12. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US 300 Patients With Cancer and COVID-19 Infection. JAMA Oncology. 2021;7(2):220-227. 301 doi:10.1001/jamaoncol.2020.6178 302 13. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of Seropositivity Following 303 BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment
- 304for Cancer. JAMA Oncology. 2021;7(8):1133-1140. doi:10.1001/jamaoncol.2021.2155
- 305 14. Fendler A, Shepherd STC, Au L, et al. Adaptive immunity and neutralizing antibodies
- 306 against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the
- 307 CAPTURE study. Nature Cancer. 2021/10/27 2021;doi:10.1038/s43018-021-00274-w
- 308 15. 2020 G. Accessed January 12th, 2022, https://gco.iarc.fr/
- 309 16. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice
- 310 Guidelines for diagnosis, treatment and follow-up^{†}. Annals of Oncology.
- 311 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173
- 312 17. Kang SY, Kim YS, Kim Z, et al. Breast Cancer Statistics in Korea in 2017: Data from a
- 313 Breast Cancer Registry. *J Breast Cancer*. 4/ 2020;23(2):115-128.
- 314 18. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-
- 315 19 vaccination among patients with cancer. Cancer Cell. 2021/08/09/ 2021;39(8):1081-
- 316 1090.e2. doi:https://doi.org/10.1016/j.ccell.2021.06.002
- 317 19. Oosting S VdVA, GeurtsvanKessel CH, et al. Vaccination against SARS-CoV-2 in
- 318 patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors.

- 319 *Annals of Oncology* 2021;32(supplement 5):S1283-S1346.
- 320 20. Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-
- 321 2 in symptomatic COVID-19 is persistent and critical for survival. *Nature Communications*.
- 322 2021/05/11 2021;12(1):2670. doi:10.1038/s41467-021-22958-8
- 323 21. Dolscheid-Pommerich R, Bartok E, Renn M, et al. Correlation between a quantitative
- 324 anti-SARS-CoV-2 IgG ELISA and neutralization activity. Journal of Medical Virology.
- 325 2022;94(1):388-392. doi:https://doi.org/10.1002/jmv.27287
- 326 22. Salazar E, Kuchipudi SV, Christensen PA, et al. Relationship between Anti-Spike Protein
- 327 Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.
- 328 *bioRxiv*. 2020:2020.06.08.138990. doi:10.1101/2020.06.08.138990
- 329 23. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2
- infection persist for months. *Science*. 2020;370(6521):1227-1230.
 doi:doi:10.1126/science.abd7728
- 332 24. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of
- 333 Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine. 2021;384(19):1824-
- 334 1835. doi:10.1056/NEJMoa2034201
- 335 25. Joona TB, Digkas E, Wennstig A-K, et al. Influenza vaccination in breast cancer patients
- 336 during subcutaneous trastuzumab in adjuvant setting. *Breast Cancer Research and Treatment*.
- 337 2020/11/01 2020;184(1):45-52. doi:10.1007/s10549-020-05815-y
- 338 26. Fischer L, Gerstel PF, Poncet A, et al. Pneumococcal polysaccharide vaccination in adults
- 339 undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study.
- 340 Arthritis Res Ther. Jun 6 2015;17(1):151. doi:10.1186/s13075-015-0663-9
- 341 27. Yang J, Ko J-H, Baek JY, et al. Effects of Short-Term Corticosteroid Use on
- 342 Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine.
- 343 Perspective. Frontiers in Immunology. 2021-September-22

344 2021;12(3908)doi:10.3389/fimmu.2021.744206

345

347 Figures and Tables

- 348 Figure 1. Patient enrollment: Flowchart showing the patient enrollment and selection
- 349 Figure 2. Proportion of seroconversion in patients: Seroprevalence proportions in (A) all
- 350 early breast cancer patients, (B) with cytotoxic chemotherapy treatments, (C) with non-
- 351 cytotoxic treatments, and (D) without anti-cancer treatment.
- 352 Figure 3. Antibody titers with Anti-Cancer treatments: SARS-CoV-2 anti-S IgG antibody
- 353 titers after each dose of vaccinations in early breast cancer patients with cytotoxic
- 354 chemotherapy treatment, with non-cytotoxic treatment, and without anti-cancer treatment
- 355 Figure 4. Antibody titers with steroid treatments in chemotherapy group: Comparison of
- 356 SARS-CoV-2 anti-S IgG antibody titers after each dose of vaccinations with and without
- 357 corticosteroid treatments in cytotoxic chemotherapy group
- 358
- 359 Table 1. Patients' characteristics
- 360 Table 2. Antibody titers with Anti-Cancer treatments

362 Supplementary Figures & Tables

- 363 Figure S1. Antibody titers with vaccinations in all patients: SARS-CoV-2 anti-S IgG titers
- after each dose of vaccinations in all early breast cancer patients
- 365 Figure S2. Antibody titers by vaccine types: SARS-CoV-2 anti-S IgG titers after each dose of
- 366 Adenoviral vaccines and mRNA vaccines
- 367 Figure S3. Antibody titers with steroid use: SARS-CoV-2 anti-S IgG titers in adjunct with
- steroid use of more than or equivalent to prednisolone 10mg within 14 days of each dose ofvaccinations
- 370
- 371 Table S1. Seroprevalence of early breast cancer patients
- 372 Table S2. Characteristics of Patients who Failed Seroconversion
- 373 Table S3. Univariable logistic regression analysis for seropositivity
- 374 Table S4. Univariable Linear Regression Analysis for OD values
- 375 Table S5. Multiple Regression Analysis for OD values

377 Data availability

378	The datasets generated during and/or analyzed during the current study are available from the
379	corresponding author on reasonable request.
380	
381	Acknowledgments
382	We thank Areum Jo for technical support.
383	
384	Fundings
385	This work was supported in part by grant no 04-2021-0250 from the SNUH Research Fund
386	and by the Bio & Medical Technology Development Program of the National Research
387	Foundation (NRF) & funded by the Korean government (MSIT)(2021M3A9I2080498)
388	
389	Ethics declarations
390	Competing interests: The authors declare no competing interests.
391	









Table 1. Patients' characteristics

			Non-cytotoxic	<u> </u>
	All	Cytotoxic chemotherapy	anticancer treatment	No treatment
Total number	87	32 (36.8%)	37 (42.5%)	18 (20.7%)
Age (median, range)	52 (35-69)	52 (35-69)	49 (36-69)	51.5 (40-61)
Vaccine				
PZ	70 (80.5%)	22 (68.8%)	32 (86.5%)	16 (88.9%)
Moderna	9 (10.3%)	5 (15.6%)	4 (10.8%)	0 (0.0%)
Janssen	3 (3.4%)	2 (6.2%)	1 (2.7%)	0 (0.0%)
AZ	5 (5.7%)	3 (9.4%)	0 (0.0%)	2 (11.1%)
Anticancer treatments				
<28 days before the				
vaccination				
Chemotherapy only	24 (27.6%)	24 (75.0%)	0 (0.0%)	0 (0.0%)
Chemotherapy + targeted therapy	8 (9.2%)	8 (25.0%)	0 (0.0%)	0 (0.0%)
Targeted therapy	1 (1.1%)	0 (0.0%)	1 (2.7%)	0 (0.0%)
Endocrine therapy	36 (41.4%)	0 (0.0%)	36 (97.3%)	0 (0.0%)
No anticancer treatment	18 (20.7%)	0 (0.0%)	0 (0.0%)	18 (100.0 %)
Surgery<28daysbeforethevaccination	5 (5.7%)	5 (15.6%)	0 (0.0%)	0 (0.0%)

Corticosteroids				
(≥10 mg prednisolone				
equivalent) <14 days	18 (20.9%)	18 (56.2%)	0 (0.0%)	0 (0.0%)
before the				
vaccination				

Abbreviations: PZ, Pfizer; AZ, AstraZeneca.

Median (1 st -3 rd quartile)	All	Chemotherapy	Non-cytotoxic therapy	No treatment
OD ratio	0.051	0.046	0.051	0.054
(baseline)	(0.019-0.081)	(0.028-0.089)	(0.037-0.069)	(0.031-0.080)
OD ratio	2.680	0.494	4.294	3.769
$(1^{st} dose)$	(0.844-4.833)	(0.081-1.338)	(2.334-5.343)	(2.542-4.921)
OD ratio	7.028	4.388	7.249	7.152
(2 nd dose)	(3.133-7.842)	(2.381-6.927)	(6.790-7.941)	(6.817-7.901)

Table 2. Antibody titers with Anti-Cancer treatments

Abbreviations: OD, optical density.